Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Experimental approaches and drugs in development for the treatment of dementia
Autore:
Emre, M; Qizilbash, N;
Indirizzi:
Istanbul Med Sch, Dept Neurol, TR-34390 Capa Istanbul, Turkey Istanbul MedSch Capa Istanbul Turkey TR-34390 390 Capa Istanbul, Turkey
Titolo Testata:
EXPERT OPINION ON INVESTIGATIONAL DRUGS
fascicolo: 4, volume: 10, anno: 2001,
pagine: 607 - 617
SICI:
1354-3784(200104)10:4<607:EAADID>2.0.ZU;2-T
Fonte:
ISI
Lingua:
ENG
Soggetto:
NERVE GROWTH-FACTOR; THYROTROPIN-RELEASING-HORMONE; CHOLINERGIC NEURON ATROPHY; AMYLOID PRECURSOR PROTEIN; DOUBLE-BLIND MULTICENTER; ALZHEIMERS-DISEASE; APOLIPOPROTEIN-E; VASCULAR DEMENTIA; BASAL FOREBRAIN; D-CYCLOSERINE;
Keywords:
Alzheimer's disease; dementia; drug development; experimental therapy; treatment;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
101
Recensione:
Indirizzi per estratti:
Citazione:
M. Emre e N. Qizilbash, "Experimental approaches and drugs in development for the treatment of dementia", EXPERT OP I, 10(4), 2001, pp. 607-617

Abstract

Treatment of dementia can be divided as symptomatic treatment of cognitiveor non-cognitive symptoms and the treatment of underlying pathology. In the last decade the thrust of symptomatic treatment of Alzheimer's disease (AD) has been enhancement of cholinergic transmission. Besides the acetylcholinesterase inhibitors (AChE-I) currently in use, cholinergic agonists and enhancers are in development. Other therapeutic approaches directed towards neurotransmitter substitution or modulation include serotoninergic, noradrenergic substances, neuropeptides and those acting via excitatory amino acidreceptors, such as ampakines or NMDA antagonists. Introduction of atypicalneuroleptics represents the most recent development in the treatment of behavioural symptoms. Efforts to treat the underlying pathology are based on modulation of APP processing in order to decrease the accumulation of beta -amyloid, those to decrease tau hyperphosphorylation, use of nerve growth factors and those based on Apo-E modulation. Potential use of oestrogens andNSAIDs are also under investigation. Recently, vaccination with amyloid-beta peptide has been reported to be effective in an animal model of AD, thisputative vaccine is now in clinical trials. Likewise, recent studies suggest that some statins may have a prophylactic effect.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/01/20 alle ore 16:06:30